Optimized Antifibrotic Therapy on Cardiac and Pulmonary Function in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review of Diagnostic and Therapeutic Approaches
DOI:
https://doi.org/10.56294/saludcyt20251417Keywords:
Idiopathic Pulmonary Fibrosis (IPF), Antifibrotic Therapy, Cardiac Function, Pulmonary FunctionAbstract
Idiopathic Pulmonary Fibrosis (IPF) is progressive interstitial lung disease which is characterized by fibrosis of lung tissue which impair respiratory function and is seen with high mortality. Our systematic review evaluates impact of optimized antifibrotic therapies while including pirfenidone, nintedanib, and BI 1015550 on pulmonary and cardiac function in IPF patients. Comprehensive analysis with previous randomized controlled trials, cohort studies and observational data was performed to assess efficacy in slowing forced vital capacity (FVC) decline, improving prognosis and managing adverse events. Our findings indicate that antifibrotic therapies can mitigate FVC decline and reduce mortality with pirfenidone and nintedanib have shown tolerable safety profiles. BI 1015550 have also shown promising results in preventing FVC reduction and pulmonary rehabilitation alongside antifibrotic treatment improved endurance but not functional capacity. Reported limitations of the included studies include variability in study designs and potential biases from non-randomized trials. Despite these challenges antifibrotic therapies represent a critical advancement in IPF management preserving lung function and potentially enhancing quality of life.
References
Sankari, A., Chapman, K. and Ullah, S. (2024) Idiopathic pulmonary fibrosis. https://www.ncbi.nlm.nih.gov/books/NBK448162/.
Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. European Respiratory Review [Internet]. 2012 Nov 30;21(126):355–61. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9487229/
Gandhi S, Tonelli R, Murray M, Samarelli AV, Spagnolo P. Environmental causes of idiopathic pulmonary fibrosis. International Journal of Molecular Sciences [Internet]. 2023 Nov 18;24(22):16481. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10671449/
Zaman T, Lee JS. Risk Factors for the Development of Idiopathic Pulmonary Fibrosis: a Review. Current Pulmonology Reports [Internet]. 2018 Oct 15;7(4):118–25. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6777743/
Van Manen MJG, Geelhoed JJMiranda, Tak NC, Wijsenbeek MS. Optimizing quality of life in patients with idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease [Internet]. 2017 Jan 30;11(3):157–69. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5933652/
Caroa, F. M., Albertia, M. L., Campins, F., Enghelmayer, J. I., Fernández, M. E., Lancellotti, D., Papucci, T., Sebastianib, J. A., & Paulina, F. (2019). Real-Life Experience With Pirfenidone in Idiopathic Pulmonary Fibrosis in Argentina: A Retrospective Multicenter Study. Respiratory Medicine, 55(2), 75-80. https://doi.org/10.1016/j.arbr.2018.12.007
Aono, Y., Nakamura, Y., Kono, M., Nakamura, H., Yokomura, K., Imokawa, S., Toyoshima, M., Yasui, H., Hozumi, H., Karayama, M., Suzuki, Y., Furuhashi, K., Enomoto, N., Fujisawa, T., Inui, N., & Suda, T. (2020). Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 14, 1753466620953783. https://doi.org/10.1177/1753466620953783
Kataoka, K., Nishiyama, O., Ogura, T., Mori, Y., Kozu, R., Arizono, S., Tsuda, T., Tomioka, H., Tomii, K., Sakamoto, K., Ishimoto, H., Kagajo, M., Ito, H., Ichikado, K., Sasano, H., Eda, S., Arita, M., Goto, Y., Hataji, O., Fuke, S., Shintani, R., Hasegawa, H., Ando, M., Ogawa, T., Shiraishi, M., Watanabe, F., Nishimura, K., Sasaki, T., Miyazaki, S., Saka, H., Kondoh, Y., & FITNESS Study Collaborators. (2020). Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: A randomised controlled trial. Thorax, 78(8), 661-667. https://doi.org/10.1136/thoraxjnl-2020-214763
Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022). Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. New England Journal of Medicine, 386(23), 2178-2187. https://doi.org/10.1056/NEJMoa2201737
De Andrade JA, Neely ML, Hellkamp AS, Culver DA, Kim HJ, Liesching T, et al. Effect of antifibrotic therapy on survival in patients with idiopathic pulmonary fibrosis. Clinical Therapeutics [Internet]. 2023 Mar 28;45(4):306–15. Available from: https://pubmed.ncbi.nlm.nih.gov/36997445/
Hofman DE, Magrì T, Moor CC, et al. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest. 2021;160(6):1797-1808. doi:10.1016/j.chest.2021.06.049.
Feng H, Zhao Y, Li Z, Kang J. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. Ther Adv Respir Dis. 2020;14:1753466620963015. doi:10.1177/1753466620963015.
Man RK, Gogikar A, Nanda A, et al. A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review. Cureus. 2024;16(2):e54268. doi:10.7759/cureus.54268.
Noor S, Nawaz S, Chaudhuri N. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment. Adv Ther. 2021;38(1):268-277. doi:10.1007/s12325-020-01523-7.
Fleetwood K, McCool R, Glanville J, et al. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments. J Manag Care Spec Pharm. 2017;23(3-b Suppl):S5-S16. doi:10.18553/jmcp.2017.23.3-b.s5.
Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest. 2021 Nov;160(5):1751-1763.
Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L, Quaresma M, Stowasser S, Richeldi L. Antifibrotic therapy with pirfenidone and nintedanib in idiopathic pulmonary fibrosis: Real-world experience in clinical practice. Respir Res. 2019 Sep 2;20(1):203.
Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L, Quaresma M, Stowasser S, Richeldi L. Antifibrotic therapy with pirfenidone and nintedanib in idiopathic pulmonary fibrosis: Real-world experience in clinical practice. Respir Res. 2019 Sep 2;20(1):203.
Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest. 2021 Nov;160(5):1751-1763.
Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L, Quaresma M, Stowasser S, Richeldi L. Antifibrotic therapy with pirfenidone and nintedanib in idiopathic pulmonary fibrosis: Real-world experience in clinical practice. Respir Res. 2019 Sep 2;20(1):203.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Syndy Katherine Guarin-Rivera, Gabriela Patricia Guijarro Reinoso, Norma Susana Chávez Villagómez, Jonattan Palacios Torres , Dario Javier Caguate Miranda, Nicole Carolina Sotomayor Páez, Alexander David Silva, Edgar Felipe Carranza Vargas, Pedro Ergir Tomay Madrigal (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
